A Review of Atrial Septal Defects and Ventricular Septal Defects in Congenital Heart Disease and Possible Gene Therapy of the GATA4 Gene Using Retroviruses
Fisher, G.D., Johnson, L.K., Purdy, C.D., and Sanders, J.P.
2015
December 11th, 2015
Help Received: Group Project
Congenital Heart Disease (CHD) is a condition that disrupts the functionality and structure of the human heart. CHD is a growing issue, resulting in 8.1 per 1000 live births in North America, and 9.3 per 1000 live births in Asia. Globally, CHD results in 1.35 million infants born each year (Fahed et al. 2014). CHD is brought about by the inheritance of genetic predispositions, or the environment’s influence on the activation of those predispositions in the course of embryogenesis. Of all of the types of CHD present in the population, the most common are Ventricular Septal Defects (VSD) and Atrial Septal Defects (ASD).
These septal defects can develop into structural issues in the ventricular and atrial septums of the heart. VSD and ASD are characterized by the perforation and weakness of the fibers composing these septums, which results in incomplete septal closure or leakage. This may result in the mixture of non-oxygenated and oxygenated blood in the chambers of the heart (Aasal et al., 2014). Both septal defects display the same phenotypes, which includes: lethargy, labored heart rate, increased muscle fatigue, poor circulation, higher BMI, and lowered ability to process oxygen. Further symptoms include ventricular and atrial dysfunction, pulmonary hypertension, and arrhythmias of the heart (Geva, et. al., 2014). These phenotypes are due to a molecular cascade, which controls the expression of both VSD and ASD.
VSD, on a cellular level, is characterized by a distinct molecular cascade which has been directly linked to the formation of the heart during embryogenesis (Broderick, et. al., 2012). Patients with VSD and ASD have cardiomyocytes that are incapable of building complete or robust actin fibers, and as a result, never form strong smooth muscle fibers. This is due to lowered activity in a protein known as Vasodilator-stimulated phosphoprotein (VASP), which is responsible for recruiting profilin bound actin monomers for cell usage in creating actin fibers (Ali, et. al., 2015). Overexpression of VASP protein through hypomethylation leads to ASD (Gertler, et. al., 1996). Similarly, underexpression of VASP protein through hypermethylation leads to VSD. If cardiomyocytes are incapable of generating complete actin fibers that are durable enough to withstand the stress of usage, blood will be able to leak through the septal wall. This leaking leads to the common symptoms of CHD, specifically septal defects.
Heart development requires precise control of gene expression patterns, and disruption of transcriptional networks in heart development causes CHD (Wamstad et al., 2012). The disruption of this cascade usually begins with a mutation in both the Nkx2-5 and GATA4 genes, which are precursors of the molecular cascade directly involved with cardiogenesis (Misra, et.al., 2012). When operating normally, these genes regulate each other along with the expression of the Tbx-5 gene (Krause, et. al., 2004). The Tbx-5 gene, in turn, secretes a transcription factor which increases the expression of two genes, NPR-A and NPR-B (Krause, et. al., 2004). NPR-A and NPR-B both code for receptor proteins that, when bound with Atrial Natruiretic Peptide (ANP) protein, stimulates a catabolic metabolism in the cell responsible for breaking down GTP (Lowe, et. al., 1990). GTP is then broken down by the cell into cyclic guanosine monophosphate (cGMP), which is designed to bind with cGMP-dependent protein kinase (PKG) (cGMP-PKG signalling pathway, 2015). This complex that is formed then stimulates the VASP gene to be expressed more, allowing for the cardiomyocyte to build proper actin fibers,generating healthy smooth muscle for the heart. (Ali, et. al., 2015) As long as GATA4 or Nkx2-5 is mutated in an inhibitory fashion, then this entire cascade will be severely suppressed in the embryo, and VSD will likely be expressed. (Bouchard, et. al., 2008)
A patient with an inherited allele for heart disease, the wild type allele, results in the complete function of the VASP protein and, as a result, the proper formation of the ventricular septum. The mutated allele alters the function of at least one of the genes involved in the GATA4 signalling pathway. (Broderick, et. al., 2012) This alteration can inhibit the cascade directly, leading to the lowered effectiveness or activity of the VASP protein, and may directly cause ventricular septal defects in patients. There are several recorded mutations of GATA4 which directly lead to the disfunction of the gene, both in its expression and its ability to be read. The mutation rs804280 of GATA4 has been associated with VSD through the reduction of readability in GATA4; because of this inhibitory mutation, the molecular cascade leading to the secretion of the VASP protein would be stopped and ultimately cardiogenesis would be altered. (Mattapally, et. al., 2015) G296S is yet another mutation of GATA4, but this mutation is a missense mutation that leads to the lowered interaction of GATA4 with Tbx-5, creating a disconnect in the molecular cascade,which results in little to no VASP secretion, ultimately generating a VSD phenotype. (Misra, et. al., 2012)
The development of patients with VSD and ASD may be strongly affected by environmental factors that they were exposed to in utero. Similarly, smoking in the mother, exposure to Bisphenol A (BPA), and air pollution have also been correlated with the incidence of congenital heart disease being developed in offspring. Maternal exposure to BPA during pregnancy may induce the ventricular septal variation of CHD by binding to the NPR-A and NPR-B receptors in an embryo, inhibiting the stimulation of guanyl-cyclase metabolism thereby stunting or stopping the molecular cascade necessary for cardiogenesis in the offspring. (Kang, et.al., 2014) BPA is an estrogen mimic, which is a precursor to the nitric oxide (NO) molecule through nitric oxide synthase (NOS). BPA induces oxidative stress on the NOS, causing a under or over expression of NO. (Chouhan et al. 2015) This molecule is used in the excitement of the cGMP-PKG complex and helps with binding affinity to the VASP protein. With low nitric oxide levels, binding of the VASP protein and the cGMP-PKG complex can not be completed correctly, leading to a misuse of the VASP protein. A plausible line of effect has also been drawn between perfluoroctanes (PFO’s), a chemical emission and common air pollutant, and the development of VSD in embryo’s. PFO’s inhibit the activity of Pol β, a polymerase used to correct mutations in DNA through excision repair. If this enzyme is inhibited, the mutation of a gene in the molecular cascade used in cariogenesis could lead to a lack of VASP protein activity, and consequently the malformation of the ventricular septum. (Nakamura, et. al., 2007)
Changes in genomes are not the only alterations that may lead to the creation of the VSD phenotype in offspring. The alteration of an epigenome may also create congenital heart disease through the silencing or overexpression of key genes. Smoking during pregnancy can alter the epigenome of the respective embryo through DNA methylation. (Lee, et. al., 2013) Chemical components of cigarette smoke have been proven to recruit DNA methyltransferase (DNMT) to cells exposed to the smoke. DNMT’s are enzymes involved with DNA methylation, and may methylate key genes involved with the molecular cascade that guides cardiogenesis in embryos. (Jin, et. al., 2013) If DNMT’s hypermethylate VASP, causing gene silencing, then the cascade leading to VASP protein activity will be inhibited or nullified, and ventricular septal formation will not execute properly. (Lee, et. al., 2013) VSD may also be induced and inheritable due to methylation of genes during folliculogenesis (maturation of the ovarian follicle) in diabetic conditions. Mothers with diabetes during pregnancy expose their oocytes to diabetic extracellular environments, which are poor in nutrients; this effectively lowers the overall metabolism of the cell, and as a result, the cells have lowered enzymatic activity and poor gene expression. (Ge, et. al., 2013) Lowered gene expression in these cells leads to the lack of secretion of proteins that are instrumental in the operation of cardiogenesis. Epigenetic alterations, like smoking may also create other septal defects, such as ASD. The hypomethylation of any genes in the molecular cascade leading to VASP brought on by exposure to cigarette smoke has been shown to create Atrial Septal Defects (ASD) in embryos, rather than VSD (Gertler, et. al., 1996).
Cure
This cure is a theoretical, one-treatment solution, specifically in patients who suffer from VSD due to a mutated copy of the gene GATA4. In light of the molecular cascade caused by GATA4, illustrated in the flow chart attached, and its imperative role in the proper conduction of cardiogenesis, this cure seeks to nullify the negative effects of a faulty copy of the GATA4 gene. It has been designed to work only for fetuses who exhibit ASD and VSD as a result of a broken copy of GATA4.
This would entail the use of a retrovirus carrying the correct copy of GATA4 being injected directly into the fetus’ heart using an amniocentesis needle. The cardiac catheterization or the amniocenteis needle in this case, is used when there is no ability to perform surgery, because of the pregnancy it would be a less invasive alternative for altering the heart of the fetus.(Minette et al. 2006) This needle would incorporate the correct form of the gene into the dividing cells of the heart as the fetus grows through the use of transduction. Because the original copy of GATA4 in the fetus is broken, the insertion of a correctly functioning gene copy should allow for the cells to express GATA4, in turn generating the cascade that leads to genesis of a properly formed septum. Although development of the heart is already structurally completed by the time of treatment, most of the growth of the organ remains. Due to this potential in cell development, the constitution of the ventricular septum may still be partially compensated for in its structure by the expression of the remaining correct copies of GATA4 (Moorman, et. al., 2003).
Patient progress should be documented and monitored using ultrasound or any viable high resolution three dimensional imaging system in order to clearly track the continuing development of the heart. A 40-MHz ultrasound could show the progress over the development and show structural integrity of the given area, this has already been shown in a recent study on mice that this could work (Srinivasan et al. 1998)
In an ideal setting and outcome, the ventricular septum should show gradual thickening over a long period of time. Secondarily, the level of blood oxygenation in the patient should be a good indicator of effectiveness of ventricular septal thickening. This is due to the lack of blood mixing through the ventricular septum, as was previously occurring in trace amounts before treatment. A good response to treatment in the patient should be characterized by the oxygenation of the arterial blood in the patient should be much higher after a month or so of cell growth.
Not all patients will be eligible for this kind of treatment, unfortunately. Patients affected with CHD who do not suffer from a septal defect, will not be able to be treated by this proposed cure. While this treatment may not be universal in its application, it is a viable way to administer a gene therapy to a developing child that may be afflicted with the disease. Of course, there must be reasonable evidence that the child is going to be afflicted with VSD when it is born, due to the dangerous nature of the procedure, and the likelihood of terminating the pregnancy should the procedure fail.
Gene expression flowchart of CHD
WORKS CITED
Aasa1, K.L., Purssell, E., Adams, M.A., and Ozolinš, T.R.S. 2014. In utero dimethadione
exposure causes postnatal disruption in cardiac structure and function in the rat.
Toxicology Sciences. 142(2): 350-360.
Ali, M., Rogers, L.K., Pitari, G.M., 2015. Serine phosphorylation of vasodilator-stimulated phosphoprotein (VASP) regulates colon cancer cell survival and apoptosis. Life Sciences, 123: 1-8.
Bennett, O., Kandala, N. B., Ji, C., Linnane, J., and Clarke, A. 2014. Spatial variation of heart
failure and air pollution in Warwickshire, UK: an investigation of small scale
variation at the ward-level. BMJ Open. 4(12).
Bouchard, M., Taniguchi, H., and Viger, R. 2008. The effect of human GATA4 gene mutations
on the activity of target gonadal promoters. Society for Endocrinology. 42: 149-160.
Bouveret R., Waardenberg A., Schonrock N., Ramialison M., Doan T., de Jong D., Bondue A., Kaur G., Mohamed S., Fonoudi H., Chen C., Wouters M., Bhattacharya S., Plachta N., Dunwoodie S., Chapman G., Blanpain C., Harvey R. 2015. , NKX2-5 mutations causative for congenital heart disease retain functionality and are directed to hundreds of targets. Life, 4: e06942.
Brite, J., Laughon, S.K., Troendle, J., and Mills, J. 2014. Maternal overweight and obesity and
risk of congenital heart defects in offspring. Internal Journal of Obesity. 38(6): 878– 882.
Broderick, T.L., Jankowski, M., Wang, D., Danalache, B.A., Parrott, C.R., and Gutkowska, J.
- Downregulation in GATA4 and downstream structural and contractile genes in the
db/db mouse heart. ISRN Endocrinology. 2012: 1-12.
Chouhan, S., Yadav, S.K., Prakash, J., Westfall, S., Ghosh, A., Agarwal, N.K., Singh, S.P. 2015.
Increase in the expression of inducible nitric oxide synthase on exposure to bisphenol A: A possible cause for decline in steroidogenesis in male mice. Environmental Toxicology and Pharmacology. 39:1.
cGMP-PKG signalling pathway, Kyoto Encyclopedia of Genes and Genomes, 2015. 04022, Web. 2 December, 2015.
Cresci, M., Foffa, I., Ait-Ali, L., Pulignani, S., Gianicolo, E., Botto, N., Picano, E., Andreassi, M. 2011. Maternal and paternal environmental risk factors, metabolizing GSTM1 and GSTT1 polymorphisms, and congenital heart disease. The American Journal of Cardiology, 108(11):1625–1631.
Fahed, A.C., Gelb, B.D., Seidman, J.G., and Seidman, C.E. 2013. Genetics of congenital heart
disease: the glass half empty. Circulation Research. 112: 707-720.
Feng, Y., Yu, Y.,Yin, M., Hong, L., and Cai, W. 2012. Ectopic expression of retinoic acid
receptors and change of myocardial structure in the offspring heart with vitamin A deficiency. Clinical Nutrition Center. 58: 309-318.
Garg, V., Kathiriya, I.S., Barnes, R., Schluterman, M.K., King, I.N., Butler, C.A., Rothrock,
C.R., Eapen, R.S., Hirayama-Yamada, K., Joo, K., Matsuoka, R., Cohen, J.C., and Srivastava, D. 2003. GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature, 424: 443-447.
Ge, Z-J., Liang, X-W., Guo, L., Liang, Q-X., Luo, S-M., Wang, Y-P., Wei, Y-C., Han, Z-M.,
Schatten, H., Sun, Q-Y. 2013. Maternal diabetes causes alterations of DNA methylation statuses of some imprinted genes in murine oocytes. Biology of Reproduction. 88(5): 117.
Gertler, F.B., Niebuhr, K., Reinhard, M., Wehland, J., and Soriano, P. 1996. Mena, a relative of
VASP and drosophila enabled, is implicated in the control of microfilament dynamics. Cell, 87(2): 227-239.
Geva, T., Martins, J.D., Wald, R.M. 2014. Atrial septal defects. The Lancet. 383(9932).
He, D., Liu, Z., Chen, L. 2011. Identification of dysfunctional modules and disease genes in congenital heart disease by a network-based approach, BMC Genomics, V.12: 592.
Huber, B.E., Richards, C.A., Krenitsky, T.A. 1991. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Medical Sciences. 88: 8039-8043.
Jin, B. and Robertson, K.D. 2013. DNA methyltransferases (DNMTs), DNA damage repair, and
cancer. Advances in Experimental Medicine and Biology, 754: 3-29.
Kang, S.Y., Song,J.Y., and Cho, H.H. 2014. Gene expression analysis of uterine smooth muscle
cells exposed to Bisphenol A. Toxicology and Environmental Health Sciences. 6(4): 261-267.
Khan, R.C. and Halder, D. 2014. Effect of seasonal variation on hospital admission due to
cardiovascular disease – findings from an observational study in a divisional hospital
in Bangladesh. BMC Cardiovascular Disorders, 14: 76.
Krause, A. , Zacharias, W. , Camarata, T. , Linkhart, B. , Law, E. , Lischke, A. , Miljan, E. , Simon, H.. 2004. Tbx5 and Tbx4 transcription factors interact with a new chicken PDZ-LIM protein in limb and heart development. Developmental Biology. 273(1):106-120.
Lee, K.W.K., and Pausova, Z. 2013. Cigarette smoking and DNA methylation. Frontiers in
Genetics. 4:132.
Lin, X., Huo, Z., Liu, X., Zhang, Y., Li, L., Zhao, H., Yan, B., Liu, Y., Yang, Y., and Chen, Y-H. 2010. A novel GATA6 mutation in patients with tetralogy of Fallot or atrial septal defect. Journal of Human Genetics, 55: 662-667.
Lowe, D.G., Klisak, I., Sparkes, R.S., Mohandas, T., Goeddel, D.V., 1990. Chromosomal
distrubution of three members of the human natriuretic peptide receptor/guanyl cyclase gene family. Molecular Biology Department, Genentech, Inc., South San Francisco, California, 8(2): 304-12.
Mattapally, S., Nizamuddin, S., Murthy, K.S., Thangaraj, K., and Banerjee, S.K. 2015.
c.620C>T mutation in GATA4 is associated with congenital heart disease in South India. BMC Medical Genetics, 16:7.
Minette, M.S., Sahn, D.J. 2006. Congenital heart disease for the adult cardiologist. American
Heart Association. 114: 2190-2197.
Misra, C., Sachan, N., McNally, C.R., Koenig, S.N., Nichols, H.A., Guggilam, A., Lucchesi,
P.A., Pu, W.T., Srivastava, D., and Garg, V. 2012. Congenital heart disease–causing gata4 mutation displays functional deficits in vivo. PLOS Genetics. 8(5).
Moorman, A., Webb., S., Brown, N.A., Lamers, W., and Anderson, R.H. 2003. Development of
the heart: (1) formation of the cardiac chambers and arterial trunks. Heart, 89(7): 806–814.
Nakamura, R., Takeuchi, R., Kuramochi, K., Mizushina, Y., Ishimaru, C., Takakusagi, Y.,
Takemura, M., Kobayashi, S., Yoshida, H., Sugawara, F., and Sakaguchi, K. 2007. Chemical properties of fatty acid derivatives as inhibitors of DNA polymerases. Organic & Biomolecular Chemistry. (24): 3912-3921.
NKX2-5 Gene, NCBI, 2015. 1482, Web. 18 November 2015.
Shi H., Yang S., Liu Y., Huang P., Lin N., Sun X., Yu R., Zhang Y., Qin Y., Wang L.2015.
Study on environmental causes and SNPs of MTHFR, MS and CBS genes related to congenital heart disease. PLoS One, 10(6): e0128646.
Srinivasan, S., Baldwin, H.S., Aristizabel, O., Kwee, L., Labow, M., Artman, M., and Turnbull,
D.H. 1998. Noninvasive, in utero imaging of mouse embryonic heart development with 40-MHz echocardiography. Circulation, 98: 912-918.
Wamstad J., Alexander J., Truty R., Shrikumar A., Li F., Eilertson K., Ding H., Wylie J., Pico
A., Capra J., Erwin G., Kattman S., Keller G., Srivastava D., Levine S., Pollard K., Holloway A., Boyer L., Bruneau B. 2012. Dynamic and coordinated epigenetic regulation of developmental transitions in the cardiac lineage. Cell, 151(1):206-20.